D Parlier

D Parlier

Affiliations

Service d'hépato-gastroentérologie, Hôpital Ambroise Paré, Boulogne-Billancourt, France.

Réseau de co-auteurs

Emma Clark 2 collaborations

Marion Procter 2 collaborations

Damien Parlier 2 collaborations

C Barsamian 1 collaboration

C Carette 1 collaboration

M Sasso 1 collaboration

T Poghosyan 1 collaboration

P Bedossa 1 collaboration

J F Emile 1 collaboration

V Miette 1 collaboration

J L Bouillot 1 collaboration

S Czernichow 1 collaboration

C Rives-Lange 1 collaboration

E de Azambuja 1 collaboration

E Agostinetto 1 collaboration

M Procter 1 collaboration

D Eiger 1 collaboration

N Pondé 1 collaboration

S Guillaume 1 collaboration

M Lambertini 1 collaboration

A Desmet 1 collaboration

C Caballero 1 collaboration

C Aguila 1 collaboration

G Jerusalem 1 collaboration

J M Walshe 1 collaboration

E Frank 1 collaboration

J Bines 1 collaboration

S Loibl 1 collaboration

M Piccart-Gebhart 1 collaboration

M S Ewer 1 collaboration

S Dent 1 collaboration

C Plummer 1 collaboration

T Suter 1 collaboration

None None 1 collaboration

José Bines 1 collaboration

Claire Barton 1 collaboration

Eleonora Restuccia 1 collaboration

Amir Sonnenblick 1 collaboration

Debora Fumagalli 1 collaboration

Amal Arahmani 1 collaboration

José Baselga 1 collaboration

Giuseppe Viale 1 collaboration

Linda L Reaby 1 collaboration

Elizabeth Frank 1 collaboration

Richard D Gelber 1 collaboration

Martine Piccart 1 collaboration

Christian Jackisch 1 collaboration

Jennifer A Petersen 1 collaboration

Maria Alice Franzoi 1 collaboration

Chris Twelves 1 collaboration

Noam Ponde 1 collaboration

Daniel Eiger 1 collaboration

Orianne Emond 1 collaboration

Sébastien Guillaume 1 collaboration

Linda Reaby 1 collaboration

Evandro de Azambuja 1 collaboration

Jose Bines 1 collaboration

Affiliations

Publications (4)

Diagnostic of hepatic fibrosis with the XL probe of the Fibroscan versus biopsies in patients candidates to bariatric surgery.

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer.

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.

Réseau de co-auteurs